Business Description
Nkarta Inc
NAICS : 541714
SIC : 2834
6000 Shoreline Court, Suite 102, South San Francisco, CA, USA, 94080
Description
Nkarta Inc is a biopharmaceutical company developing engineered natural killer (NK) cells to fight cancer. The company is focused on leveraging the natural potent power of NK cells to identify and kill abnormal cells and recruit adaptive immune effectors to generate responses that are specific and durable. It is combining its NK expansion platform technology with proprietary cell engineering technologies to generate an abundant supply of NK cells, engineer enhanced NK cell recognition of tumor targets, and improve persistence for sustained activity in the body for the treatment of cancer. The company's operations are based in South San Francisco, California and it operates in one segment.
Financial Strength
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 3.13 | |||||
| Equity-to-Asset | 0.75 | |||||
| Debt-to-Equity | 0.3 | |||||
| Debt-to-EBITDA | -0.76 | |||||
| Interest Coverage | N/A |
N/A
|
N/A
| |||
| Piotroski F-Score | 2/9 | |||||
| Altman Z-Score | 0 | |||||
| Beneish M-Score | 0 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | -100 | |||||
| 3-Year EBITDA Growth Rate | -423.1 | |||||
| 3-Year EPS without NRI Growth Rate | -262.5 | |||||
| 3-Year FCF Growth Rate | -23.4 |
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 84.79 | |||||
| 9-Day RSI | 74.18 | |||||
| 14-Day RSI | 67.41 | |||||
| 6-1 Month Momentum % | 47.2 | |||||
| 12-1 Month Momentum % | -62.37 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 20.59 | |||||
| Quick Ratio | 20.59 | |||||
| Cash Ratio | 20.01 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -87.2 |
Profitability Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| ROE % | -34.48 | |||||
| ROA % | -30.74 | |||||
| ROIC % | -213.74 | |||||
| ROC (Joel Greenblatt) % | -267.3 | |||||
| ROCE % | -32.04 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PB Ratio | 2.31 | |||||
| Price-to-Tangible-Book | 2.31 | |||||
| EV-to-EBIT | -6.76 | |||||
| EV-to-Forward-EBIT | -5.59 | |||||
| EV-to-EBITDA | -6.88 | |||||
| EV-to-FCF | -7.41 | |||||
| Price-to-Net-Current-Asset-Value | 3.63 | |||||
| Price-to-Net-Cash | 3.79 | |||||
| Earnings Yield (Greenblatt) % | -14.84 |
Guru Trades
See DetailsEMBED
SAVE
Insider Trades
See DetailsEMBED
SAVE
Gurus Latest Trades with NAS:NKTX
Executives
EMBED
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 0 | ||
| EPS (TTM) ($) | -2.82 | ||
| Beta | 0 | ||
| Volatility % | 96.8 | ||
| 14-Day RSI | 67.41 | ||
| 14-Day ATR ($) | 1.043082 | ||
| 20-Day SMA ($) | 13.758 | ||
| 12-1 Month Momentum % | -62.37 | ||
| 52-Week Range ($) | 7.55 - 40.64 | ||
| Shares Outstanding (Mil) | 48.4 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 2 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Nkarta Inc Filings
| Document | Form | Filing Date | ||
|---|---|---|---|---|
| No Filing Data | ||||